Summary

Eligibility
for people ages 18-120 (full criteria)
Location
at UC Irvine UCSD
Dates
study started
study ends around

Description

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma.

PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Official Title

Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas

Details

Keywords

Brain and Central Nervous System Tumors, Neurotoxicity, adult diffuse astrocytoma, adult oligodendroglioma, recurrent adult brain tumor, adult mixed glioma, Glioma, Nervous System Neoplasms, Central Nervous System Neoplasms, Neurotoxicity Syndromes, Temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy

Eligibility

Locations

  • Rebecca and John Moores UCSD Cancer Center
    La Jolla California 92093-0658 United States
  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
    Orange California 92868 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eastern Cooperative Oncology Group
ID
NCT00978458
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 540 people participating
Last Updated